Overview

Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions

Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
0
Participant gender:
All
Summary
Dexmedetomidine is a unique sedative medication able to provide sedation without causing respiratory depression and maintaining neurological functions. Patients having an acute ischemic stroke and need to undergo endovascular therapy require constant assessment of their neurological status prior, during and after the interventional procedure. In this study the investigators will compare the efficacy of Dexmedetomidine to other standard sedative medications in providing optimal sedative effect while maintaining neurological function.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborators:
Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer
Treatments:
Dexmedetomidine
Fentanyl
Midazolam
Criteria
Inclusion Criteria:

- Patients with acute ischemic stroke who require endovascular intervention with whom
mNIHSS score can be obtained

- Patients with cerebral vasospasm suspiciousness with or without subarachnoid
hemorrhage with whom mNIHSS score can be obtained.

Exclusion Criteria:

- History of severe hepatic disease or severe renal disease (GFR<20).

- Hemodynamic instability.

- Pregnancy.

- Known allergy to study drug.

- Evidence or history of cardiac electrophysiology instability including uncontrolled
hemodynamically unstable complex atrial/ventricular arrhythmia or conduction block at
the time of evaluation with the exception of atrial fibrillation, and heart rate less
than 60 or systolic blood pressure less than 90.

- Respiratory compromise requiring intubation.

- Any medical (including history of cardiac conduction block, major hepatic or renal
disease) or laboratory abnormality that may increase the risk associated with the
trial participation or drug administration or may interfere with interpretation of
trial results.